NYSE:CANF Can-Fite BioPharma (CANF) Stock Price, News & Analysis $3.38 -0.08 (-2.43%) As of 12:58 PM Eastern This is a fair market value price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsHeadlinesOwnershipSEC FilingsTrendsBuy This Stock About Can-Fite BioPharma Stock (NYSE:CANF) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Can-Fite BioPharma alerts:Sign Up Key Stats Today's Range$3.22▼$3.4650-Day Range$2.91▼$4.2052-Week Range$2.83▼$23.40Volume8,476 shsAverage Volume761,925 shsMarket Capitalization$2.21 millionP/E RatioN/ADividend YieldN/APrice Target$42.50Consensus RatingModerate Buy Company Overview Can-Fite BioPharma Ltd. is a clinical-stage biopharmaceutical company headquartered in Petah Tikva, Israel, that focuses on the development of small molecule drugs for the treatment of inflammatory, oncology and liver diseases. Established in 1994, the company leverages its proprietary technology platform centered on modulating the adenosine receptor system to advance novel therapeutic candidates. Can-Fite’s research and development efforts are directed toward addressing significant unmet medical needs in autoimmune and cancer indications. The company’s lead product candidates include piclidenoson (CF101) and namodenoson (CF102). Piclidenoson is being evaluated for the treatment of rheumatoid arthritis and psoriasis, with pivotal studies designed to demonstrate efficacy and safety in patients who have shown inadequate responses to existing therapies. Namodenoson is in clinical development for hepatocellular carcinoma and nonalcoholic steatohepatitis (NASH), conditions with limited treatment options and high unmet demand. Can-Fite’s pipeline also features earlier-stage programs aimed at expanding the application of its adenosine receptor technology across additional therapeutic areas. Can-Fite conducts its clinical trials in multiple geographies, including North America, Europe and Israel, collaborating with leading research institutions and contract research organizations to ensure rigorous study design and execution. The company has entered into strategic partnerships and licensing agreements to facilitate development, regulatory filing and potential commercialization of its product candidates. These collaborations are intended to extend Can-Fite’s global reach and leverage external expertise to accelerate development timelines. Under the leadership of Chief Executive Officer Pnina Fishman, Can-Fite has maintained a focused strategy on clinical advancement and regulatory engagement. The management team brings extensive experience in biopharmaceutical development, regulatory affairs and commercial strategy. Looking ahead, Can-Fite aims to complete late-stage trials for its lead candidates, pursue regulatory approvals, and explore additional indications for its adenosine receptor platform to deliver new treatment options for patients worldwide.AI Generated. May Contain Errors. Read More Can-Fite BioPharma Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks57th Percentile Overall ScoreCANF MarketRank™: Can-Fite BioPharma scored higher than 57% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.9 / 5Analyst RatingModerate Buy Consensus RatingCan-Fite BioPharma has received a consensus rating of Moderate Buy. The company's average rating score is 2.67, and is based on no strong buy ratings, 2 buy ratings, 1 hold rating, and no sell ratings.Upside PotentialCan-Fite BioPharma has a consensus price target of $42.50, representing about 1,161.1% upside from its current price of $3.37.Amount of Analyst CoverageCan-Fite BioPharma has only been the subject of 3 research reports in the past 90 days.Read more about Can-Fite BioPharma's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Can-Fite BioPharma are expected to grow in the coming year, from ($1.25) to ($0.05) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Can-Fite BioPharma is -1.88, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Can-Fite BioPharma is -1.88, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCan-Fite BioPharma has a P/B Ratio of 1.91. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Short InterestN/AShort Interest LevelN/A Short InterestThere is no current short interest data available for CANF. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldCan-Fite BioPharma does not currently pay a dividend.Dividend GrowthCan-Fite BioPharma does not have a long track record of dividend growth. News and Social Media3.7 / 5News Sentiment0.86 News SentimentCan-Fite BioPharma has a news sentiment score of 0.86. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.39 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Can-Fite BioPharma this week, compared to 1 article on an average week.Search Interest7 people have searched for CANF on MarketBeat in the last 30 days. This is an increase of 600% compared to the previous 30 days. Company Ownership0.3 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Can-Fite BioPharma insiders have not sold or bought any company stock.Percentage Held by Insiders0.80% of the stock of Can-Fite BioPharma is held by insiders.Percentage Held by Institutions21.00% of the stock of Can-Fite BioPharma is held by institutions.Read more about Can-Fite BioPharma's insider trading history. Receive CANF Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Can-Fite BioPharma and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. CANF Stock News HeadlinesScientific Publication of Can-Fite and Vetbiolix Validates Piclidenoson’s Potential in the Multi-Billion Dollar Canine Osteoarthritis MarketMay 18 at 9:33 AM | markets.businessinsider.comScientific Publication of Can-Fite and Vetbiolix Validates Piclidenoson's Potential in the Multi-Billion Dollar Canine Osteoarthritis MarketMay 18 at 7:00 AM | globenewswire.comLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top S&P 500 stock for 12 years running—and today, he's giving away his #1 AI stock pick for 2026, free. This company's sales are up 28% year over year, it holds over 30,000 patents in wireless and video technology, and it just earned an A-rating in his proprietary Stock Grader system that has cost him $9 million to build and maintain.May 21 at 1:00 AM | InvestorPlace (Ad)D Boral Capital upgrades Can-Fite BioPharma - Depositary Receipt (CANF)May 16, 2026 | msn.comFollowing Positive Phase 2a Pancreatic Cancer Data, Can-Fite Advances Namodenoson into Phase 2b Combination Study with ImmunotherapyMay 13, 2026 | globenewswire.comCan-Fite Reports Positive Phase 2a Data with Namodenoson in Pancreatic Cancer; 35% of Patients Remain on Therapy, Including One Beyond 16 MonthsApril 30, 2026 | globenewswire.comCan-Fite BioPharma Ltd. Sponsored ADRMarch 31, 2026 | edition.cnn.comCan-Fite’s Partner Vetbiolix Completes Enrollment in Phase 2 Osteoarthritis Study in Dogs Treated with Piclidenoson; Data Expected in Q3 2026March 30, 2026 | markets.businessinsider.comSee More Headlines CANF Stock Analysis - Frequently Asked Questions How have CANF shares performed this year? Can-Fite BioPharma's stock was trading at $4.00 at the beginning of 2026. Since then, CANF shares have decreased by 15.8% and is now trading at $3.37. How were Can-Fite BioPharma's earnings last quarter? Can-Fite BioPharma Ltd. (NYSE:CANF) released its earnings results on Tuesday, November, 30th. The company reported ($38.00) earnings per share (EPS) for the quarter, missing the consensus estimate of ($18.00) by $20.00. The business earned $0.25 million during the quarter. When did Can-Fite BioPharma's stock split? Shares of Can-Fite BioPharma reverse split before market open on Monday, January 5th 2026.The 1-20 reverse split was announced on Tuesday, December 23rd 2025. The number of shares owned by shareholders was adjusted after the market closes on Sunday, January 4th 2026. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split. How do I buy shares of Can-Fite BioPharma? Shares of CANF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Can-Fite BioPharma own? Based on aggregate information from My MarketBeat watchlists, some other companies that Can-Fite BioPharma investors own include NVIDIA (NVDA), Advanced Micro Devices (AMD), Meta Platforms (META), Broadcom (AVGO), Novo Nordisk A/S (NVO) and Adobe (ADBE). Company Calendar Last Earnings11/30/2021Today5/21/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (21m+) 1-Year History May 25 Aug 25 Nov 25 Feb 26 May 26 CANF's financial health is in the Red zone, according to TradeSmith. CANF has been in this zone for over 21 months. Industry, Sector and Symbol Stock ExchangeNYSE SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNYSE:CANF CIK1536196 Webwww.canfite.com Phone972-3-924-1114Fax972-3924-9378Employees8Year FoundedN/APrice Target and Rating Average Price Target for Can-Fite BioPharma$42.50 High Price Target$80.00 Low Price Target$5.00 Potential Upside/Downside+1,161.1%Consensus RatingModerate Buy Rating Score (0-4)2.67 Research Coverage3 Analysts Profitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current Ratio2.93 Quick RatioN/A Sales & Book Value Annual Sales$405 thousand Price / Sales5.45 Cash FlowN/A Price / Cash FlowN/A Book Value$1.76 per share Price / Book1.91Miscellaneous Outstanding Shares655,000Free FloatN/AMarket Cap$2.21 million OptionableNot Optionable Beta1.09 The Best Nuclear Energy Stocks to BuyNuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.Get This Free Report This page (NYSE:CANF) was last updated on 5/21/2026 by MarketBeat.com Staff. From Our PartnersSpaceX eyes a 1.75 trillion valuation - here's what to knowElon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a...Brownstone Research | SponsoredIran's New Leader Just Said Something That Should Terrify Every AmericanIran's Supreme Leader has declared the Strait of Hormuz closed as leverage against the U.S. - and with 40% of ...American Alternative | Sponsored$30 stock to buy before Starlink goes public (WATCH NOW!)In the next 3 minutes… James Altucher – legendary investor and venture capitalist… And someone who’s kno...Paradigm Press | SponsoredTrump's gold order: the announcement they won't put on the front pageOn August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredYour book attachedYour Download Link (Expiring) If you still haven't downloaded the free Simple Options Trading For Beginners...Profits Run | SponsoredMy feud with Zohran MamdaniEmmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...Stansberry Research | SponsoredIran War Shock: What I Was Told In That Private MeetingYou’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...Banyan Hill Publishing | SponsoredWhy this tiny stock may move before the SpaceX IPO dropsThe projected SpaceX and xAI S-1 filing hits the SEC on June 1st - and analyst Dylan Jovine says $1.75 trillio...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Can-Fite BioPharma Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share Can-Fite BioPharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
